News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
Valneva SE announces the publication of an article on the global health and economic burden of chikungunya in The British Medical Journal, revealing higher disease burden and substantial costs -
COMMUNIQUÉ DE PRESSE
Valneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunya
Valneva SE annonce la publication d’un article sur l’impact sanitaire et économique mondial du chikungunya dans le British Medical Journal, mettant en lumière son lourd fardeau et ses coûts importants -
-
-
COMMUNIQUÉ DE PRESSE
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
Valneva submits label extension application to U.S. FDA for its chikungunya vaccine, IXCHIQ®, to potentially include adolescents aged 12 to 17 years and two-year antibody persistence data -
